Drug Utilization Review (DUR) Meeting Minutes

March 7, 2018

Members Present: Wendy Brown, Katie Kram, Tanya Schmidt, Laura Schield, Michael Quast, Zach Marty, LeNeika Roehrich, Andrea Honeyman, Carlotta McCleary, Peter Woodrow, Michael Booth, Russ Sobotta

Members Absent: Gaylord Kavlie, Jeffrey Hostetter,

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy, Gary Betting

Old Business

Chair W. Brown called the meeting to order at 1:04 p.m. Chair W. Brown asked for a motion to approve the minutes of the December meeting. T. Schmidt moved that the minutes be approved and L. Roehrich seconded the motion. Chair W. Brown called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Review Top 15 Therapeutic Categories/Top 25 Drugs

B. Joyce presented the quarterly review of the top 15 therapeutic classes by total cost of claims, top 25 drugs based on number of claims, and top 25 drugs based on claims cost for the 4th quarter of 2017.

PDL Update

A. Murphy shared with the Board all of changes made to the Preferred Drug List since the most recent 2018 version of the Preferred Drug List was posted. A total of forty-nine medications were removed from requiring prior authorization and nineteen medications were added to the Medical Billing Only list of medications. The following medications will now require an approved prior authorization: Admelog, Bevyxxa, Bydureon BCISE, diclofenac potassium, diclofenac sodium, diclofenac sodium ER, Duzallo, etodolac, etodolac ER, Hemlibra, Nityr, Odactra, Ozempic, piroxicam, Prevymis, Qtern, Rebinyn, Steglatro, Steglujan, Sublocade, tolmetin, Tracleer, Xhance, and Ximino.

Second Review of Skelaxin

A motion and second was made at the December meeting to place Skelaxin on prior authorization. The topics were brought up for a second review. There was no public comment. It was proposed to add a checkbox for methocarbamol and add verbiage that methocarbamol is also less sedating to the form. A motion to approve amended form and prior authorization criteria was made by K. Kram and seconded by P. Woodrow. Chair W. Brown called for a voice vote and the motion passed with no audible dissent.

Second Review of Eucrisa

A motion and second was made at the December meeting to place Eucrisa on prior authorization. The topics were brought up for a second review. Rob Hansen of Pfizer made public comment regarding drug information on Eucrisa. A motion to approve form and prior authorization criteria was made by J. Hostetter and seconded by L. Schield. Chair W. Brown called for a voice vote and the motion passed with no audible dissent.

Review of First Fill of Narcotics

B. Joyce presented information on day supply limitations and edits of other state Medicaid programs for the first fill of narcotics. The Board discussed whether any changes should be made to North Dakota's current policy. The Board requested that data be brought to the next board meeting on the current average day supply of first narcotic fills to determine if any changes needed to be made to the state policy.

New Business

Anzemet and Zuplenz

T. DeRuiter and A. Murphy reviewed Anzemet and Zuplenz with the Board. The Board proposed the creation of a chemotherapy induced nausea and vomiting criteria set and form, which Anzemet and Zuplenz would fall into. A motion was made by M. Quast to create this new PA criteria class and manage these medications through prior authorization. The motion was seconded by J. Hostetter. This topic will be reviewed at the next meeting

Biosimilar Agents

T. DeRuiter and A. Murphy reviewed biosimilar agents with the Board. A motion was made by K. Kram to manage the medications through prior authorization. The motion was seconded by P. Woodrow. This topic will be reviewed at the next meeting

Dupixent

T. DeRuiter and A. Murphy reviewed Dupixent with the Board. A motion was made by K. Kram to manage the medication through prior authorization. The motion was seconded by J. Hostetter. This topic will be reviewed at the next meeting

Gocovri

T. DeRuiter and A. Murphy reviewed Gocovri with the Board. A motion was made by K. Kram to manage the medication through prior authorization. The motion was seconded by J. Hostetter. This topic will be reviewed at the next meeting

Tussicaps

T. DeRuiter and A. Murphy reviewed Tussicaps with the Board. A motion was made by J. Hostetter to manage the medication through prior authorization. The motion was seconded by P. Woodrow. This topic will be reviewed at the next meeting

Topical Corticosteroid Agents

T. DeRuiter and A. Murphy reviewed topical corticosteroid agents with the Board. A motion was made by L. Roehrich to manage the medication through prior authorization. The motion was seconded by K. Kram. This topic will be reviewed at the next meeting

Review of Codeine and Tramadol Utilization

T. DeRuiter and B. Joyce reviewed the utilization of codeine and tramadol agents with the Board. The presented information showed utilization of the available codeine and tramadol products by age group and further evaluated utilization based on number of patients, average dose, and number of claims per month.

Review of Adderall Utilization

T. DeRuiter and B. Joyce reviewed the utilization of Adderall products with the Board. The presented information showed utilization of the available immediate release and extended release Adderall products based on number of claims and number of patients based on product and dosing strength.

Review of Proton Pump Inhibitor Utilization

T. DeRuiter and B. Joyce reviewed the utilization of proton pump inhibitors with the Board. The presented information showed utilization by drug and evaluate the number of patients on each agent that were receiving greater than once daily dose, those that had been on the medication for greater than 3 months, and those without an appropriate diagnosis for long-term PPI therapy.

Review of Hormone Therapy

B. Joyce discussed a claims processing edit in place for hormone therapies based on gender that prevented males from receiving estrogen hormone therapy and females from receiving testosterone therapy. The Board approved of the removal of these claims processing edits to allow patients of either gender to receive these products.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. T. Schmidt moved to approve the new criteria and L. Schield seconded the motion. The motion passed with no audible dissent.

Adjournment and Upcoming Meeting Date

K. Kram moved to adjourn the meeting at and P. Woodrow seconded. Chair W. Brown adjourned the meeting at 3:10 pm. The next DUR Board meeting will be held June 6, 2018 at the Capitol in the Sakakawea room in Bismarck.